Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBT Margin (2021 - 2025)

Mirum Pharmaceuticals has reported EBT Margin over the past 5 years, most recently at 3.33% for Q4 2025.

  • Quarterly results put EBT Margin at 3.33% for Q4 2025, up 2118.0% from a year ago — trailing twelve months through Dec 2025 was 4.11% (up 2169.0% YoY), and the annual figure for FY2025 was 4.11%, up 2169.0%.
  • EBT Margin for Q4 2025 was 3.33% at Mirum Pharmaceuticals, down from 1.99% in the prior quarter.
  • Over the last five years, EBT Margin for MIRM hit a ceiling of 1825.75% in Q4 2021 and a floor of 941.98% in Q3 2021.
  • Median EBT Margin over the past 5 years was 48.9% (2023), compared with a mean of 43.48%.
  • Peak annual rise in EBT Margin hit 75192bps in 2022, while the deepest fall reached -195580bps in 2022.
  • Mirum Pharmaceuticals' EBT Margin stood at 1825.75% in 2021, then crashed by -107bps to 130.05% in 2022, then skyrocketed by 61bps to 50.94% in 2023, then surged by 52bps to 24.51% in 2024, then skyrocketed by 86bps to 3.33% in 2025.
  • The last three reported values for EBT Margin were 3.33% (Q4 2025), 1.99% (Q3 2025), and 4.27% (Q2 2025) per Business Quant data.